Compare Stocks: FIJ, NC6, HEMO, and HEM

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEM Hemostemix	C$0.05 -10.0%	C$0.07	C$0.04 ▼ C$0.18	C$4.04M	0.55	41,030 shs	82,500 shs

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEM Hemostemix	-10.00%	-18.18%	-25.00%	-40.00%	-72.73%

$25,000 into $109,616 in two months? (Ad)

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEM Hemostemix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEM Hemostemix	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEM Hemostemix	N/A	N/A	C$0.00 per share	10.77	C($0.08) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEM Hemostemix	-C$3.17M	-C$0.04	N/A	∞	N/A	N/A	N/A	-165.67%	4/25/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEM Hemostemix	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEM Hemostemix	N/A	0.25	0.48

Ownership

Institutional Ownership

Company	Institutional Ownership
HEM Hemostemix	N/A

Insider Ownership

Company	Insider Ownership
HEM Hemostemix	12.15%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HEM Hemostemix	N/A	89.79 million	N/A	Not Optionable

FIJ, NC6, HEMO, and HEM Headlines

Source	Headline
	Hemostemix Inc.: Hemostemix Announces Engagement of Oak Hill Asset Management Inc. finanznachrichten.de - March 7 at 5:50 PM
	Hemostemix Announces Engagement of Oak Hill Asset Management Inc. finance.yahoo.com - March 7 at 5:50 PM
	Hemostemix: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (HEM) theglobeandmail.com - February 20 at 1:35 PM
	Hemostemix: Top 10 Undervalued Biotechnology Industry Stocks (HEM) theglobeandmail.com - February 19 at 3:14 PM
	Adverum stock stumbles on phase II gene therapy data in AMD bioworld.com - February 9 at 8:36 AM
	Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences finance.yahoo.com - February 6 at 1:36 PM
	Hemostemix Inc HMTXF morningstar.com - January 19 at 6:14 PM
	Hemostemix Inc.: Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease finanznachrichten.de - October 30 at 5:07 PM
	Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease finance.yahoo.com - October 30 at 5:07 PM
	Closing Bell: Hemostemix Inc down on Thursday (HEM) theglobeandmail.com - October 20 at 12:37 AM
	Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications finance.yahoo.com - August 29 at 3:34 PM
	Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement investorintel.com - August 14 at 6:12 PM
	Innovations for Tomorrow: The Must-Attend InvestorTalk Series of August 2023 investorintel.com - August 11 at 8:34 PM
	Closing Bell: Hemostemix Inc up on Friday (HEM) theglobeandmail.com - August 8 at 6:14 AM
	Hemostemix Inc.: Hemostemix Closes $403,539 of the Unit Private Placement finanznachrichten.de - June 28 at 9:52 AM
	Closing Bell: Hemostemix Inc up on Tuesday (HEM) theglobeandmail.com - June 28 at 9:52 AM
	Hemostemix Closes $403,539 of the Unit Private Placement finance.yahoo.com - June 28 at 9:52 AM
	Closing Bell: Hemostemix Inc down on Monday (HEM) theglobeandmail.com - June 27 at 6:21 PM
	Closing Bell: Hemostemix Inc flat on Wednesday (HEM) theglobeandmail.com - June 24 at 1:03 PM
	Hemostemix's Private Placement Use of Proceeds marketwatch.com - June 22 at 2:16 PM
	Closing Bell: Hemostemix Inc down on Friday (HEM) theglobeandmail.com - June 17 at 2:16 PM
	Hemostemix to raise $1.2M through private placement of units msn.com - June 2 at 9:56 AM
	Dr. McNorgan Discusses Hemostemix’s Stem Cell Technology and Potential with Elon Musk’s Neuralink investorintel.com - June 1 at 2:22 PM
	Thomas Smeenk Discusses the Intersection of Hemostemix’s NCP Treatment and Elon Musk’s Neuralink investorintel.com - May 5 at 4:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Hemostemix

CVE:HEM

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Compare Stocks